Breast Cancer Clinical Trial Overview

SCCA Breast Cancer Clinical Trials

The Seattle Cancer Care Alliance Breast Cancer Research Program has a multidisciplinary approach to cancer research focusing on the diagnosis and treatment of cancer with novel imaging and cancer treatment agents. We put particular emphasis on imaging trials that measure the ability of MRIs and PET imaging to predict response to treatment. We also explore targeted therapy including those treatments aimed at specific processes of cancer cell growth, division or life cycle or, in some cases, the blood vessels nourishing a tumor.

To find a clinical trial:

  • View the Breast Cancer Trial Finder, where trials are organized by disease status (e.g., "Metastatic ER", "Metastatic HER2+").
  • Click here to view a listing of all open breast cancer trials.
  • To see a list of all of SCCA's most recently opened clinical trials, follow our Twitter feed @SCCA_Trials. Likewise, the SCCABlog also regularly lists recently opened trials as well.

Our current high priority trials include:

Targeted Therapy

For patients with metastatic disease:

  • Triple Negative Gen (6628)
    Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

For patients with HER2-positive breast cancer:

Imaging Studies

For patients with newly diagnosed disease:

Our faculty also participate in cooperative group trials through the Southwest Oncology Group (SWOG), the American College of Surgeons Oncology Group (ACOSOG) and the American College of Imaging Network (ACRIN).